Keyword: EuroBiotech Report
The collaboration will see e-therapeutics apply its platform for finding synergistic target combinations to a “specific area” of Type 2 diabetes.
Having failed to improve outcomes in metastatic NSCLC, the anti-CTLA4 antibody has now missed the mark in a phase 3 head and neck cancer trial.
In this week's EuroBiotech Report, UCB commits to U.K., and Lundbeck, Genfit and AstraZeneca post midphase data.
In our EuroBiotech roundup this week, Mereo Biopharma inks deal to merge with OncoMed and Euro biotechs release a flurry of hematology data.
The readout sets Genfit up to start a pivotal trial in PBC and thereby expand its late-phase pipeline beyond NASH.
Near-term plans include the creation of a system for assessing study feasibility and an app to connect patients to studies.
The British government unveiled UCB’s investment in its second life science sector deal, which disclosed total spending of £1.3 billion.
The data give Lundbeck a boost at a time when its recently installed CEO is hunting for ways to improve on lackluster growth forecasts.
AstraZeneca moved the Dynavax-partnered TLR9 agonist into the trial in the belief it could improve time to loss of asthma control.
In this week's EuroBiotech Report, Novartis to move U.K. headquarters, Vectura fails phase 3 test and Hookipa inks R&D pact and more.